Research graph
References from Tumor mutational burden as a prognostic biomarker for survival and quality of life in metastatic colorectal cancer patients receiving anti-PD-1/PD-L1 immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Colorectal cancer.
10.1016/s0140-6736(19)32319-0 · 2019 · External reference
Diagnosis and treatment of metastatic colorectal cancer: a review.
10.1001/jama.2021.0106 · 2021 · External reference
Clinical management of metastatic colorectal cancer in the era of precision medicine.
2022 · External reference
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
10.1186/s13073-017-0424-2 · 2017 · External reference
Neoantigens in cancer immunotherapy.
10.1126/science.aaa4971 · 2015 · External reference
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
10.1016/s1470-2045(20)30445-9 · 2020 · External reference
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
10.1093/annonc/mdz134 · 2019 · External reference
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
10.1093/jnci/85.5.365 · 1993 · External reference
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer.
10.1016/j.ejca.2022.10.026 · 2023 · External reference
National and subnational incidence, mortality and associated factors of colorectal cancer in China: a systematic analysis and modelling study.
10.7189/jogh.13.04096 · 2023 · External reference
Colorectal cancer.
10.1016/s0140-6736(13)61649-9 · 2014 · External reference
Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
10.1016/j.annonc.2022.10.003 · 2023 · External reference
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
10.1038/s41588-018-0312-8 · 2019 · External reference
Prognosis and prognostic research: what, why, and how?
10.1136/bmj.b375 · 2009 · External reference
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.
10.1056/nejmoa1801946 · 2018 · External reference
Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis.
10.1001/jamanetworkopen.2019.6879 · 2019 · External reference
Immune-related adverse events associated with immune checkpoint blockade.
10.1056/nejmra1703481 · 2018 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline.
10.1200/jco.21.01440 · 2021 · External reference
Quality of life in cancer care.
10.1016/j.medj.2021.07.005 · 2021 · External reference
Health-related quality of life and cancer clinical trials.
10.1177/1758834010395342 · 2011 · External reference
Impact of precision medicine in diverse cancers: a meta-analysis of phase ii clinical trials.
10.1200/jco.2015.61.5997 · 2015 · External reference
Shared decision making--pinnacle of patient-centered care.
10.1056/nejmp1109283 · 2012 · External reference
Diagnosis and treatment of metastatic colorectal cancer: a review.
10.1001/jama.2021.0106 · ExternalCitation · doi-reference
Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis.
10.1001/jamanetworkopen.2019.6879 · ExternalCitation · doi-reference
Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
10.1016/j.annonc.2022.10.003 · ExternalCitation · doi-reference
Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer.
10.1016/j.ejca.2022.10.026 · ExternalCitation · doi-reference
Quality of life in cancer care.
10.1016/j.medj.2021.07.005 · ExternalCitation · doi-reference
Colorectal cancer.
10.1016/s0140-6736(13)61649-9 · ExternalCitation · doi-reference
Colorectal cancer.
10.1016/s0140-6736(19)32319-0 · ExternalCitation · doi-reference
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
10.1016/s1470-2045(20)30445-9 · ExternalCitation · doi-reference
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
10.1038/s41588-018-0312-8 · ExternalCitation · doi-reference
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.
10.1056/nejmoa1801946 · ExternalCitation · doi-reference
Shared decision making--pinnacle of patient-centered care.
10.1056/nejmp1109283 · ExternalCitation · doi-reference
Immune-related adverse events associated with immune checkpoint blockade.
10.1056/nejmra1703481 · ExternalCitation · doi-reference
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
10.1093/annonc/mdz134 · ExternalCitation · doi-reference
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
10.1093/jnci/85.5.365 · ExternalCitation · doi-reference
Neoantigens in cancer immunotherapy.
10.1126/science.aaa4971 · ExternalCitation · doi-reference
Prognosis and prognostic research: what, why, and how?
10.1136/bmj.b375 · ExternalCitation · doi-reference
Health-related quality of life and cancer clinical trials.
10.1177/1758834010395342 · ExternalCitation · doi-reference
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
10.1186/s13073-017-0424-2 · ExternalCitation · doi-reference
Impact of precision medicine in diverse cancers: a meta-analysis of phase ii clinical trials.
10.1200/jco.2015.61.5997 · ExternalCitation · doi-reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO clinical practice guideline.
10.1200/jco.21.01440 · ExternalCitation · doi-reference
National and subnational incidence, mortality and associated factors of colorectal cancer in China: a systematic analysis and modelling study.
10.7189/jogh.13.04096 · ExternalCitation · doi-reference
